BioCryst Pharmaceuticals Inc to Discuss the Phase 1 trial of BCX9930 - Conference Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the BioCryst Pharmaceuticals Update Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to turn your call over to John Bluth of BioCryst. You may begin.
Thank you very much, Kevin. Good morning, and welcome to our call to discuss data from our Phase I trial of BCX9930. Today's press release and accompanying slides, which include data from the Phase I trial in healthy volunteers, are available on our website.
Participating on the call with me today are CEO, Jon Stonehouse; and Chief Medical Officer, Dr. Bill Sheridan. Our CFO, Tom Staab; and our Chief Business Officer, Megan Sniecinski, are also here and will be available during our Q&A session.
Before we begin, I want to direct your attention to Slide 2, which discusses our use of forward-looking statements and potential risk factors regarding an
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |